Gossamer Bio, Inc.

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of novel therapeutics. The company's primary focus is on seralutinib, an investigational inhaled small molecule inhibitor targeting platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor, and c-KIT. This promising compound is currently undergoing Phase 3 clinical trials for the treatment of pulmonary arterial hypertension (PAH), a serious and progressive disease affecting the arteries in the lungs and the right side of the heart. Gossamer Bio holds exclusive license agreements with Pulmokine, Inc. for the development and commercialization of seralutinib and related backup compounds, underscoring a strategic approach to building a robust pipeline. By concentrating on a single, high-impact indication like PAH, Gossamer Bio aims to address a significant unmet medical need within the cardiovascular and pulmonary disease landscape. The company's business model is centered on advancing its lead asset through late-stage clinical development and ultimately bringing it to market, positioning itself as a key player in the biopharmaceutical sector focused on rare and serious diseases.